Federal health advisers have endorsed a closely watched Alzheimer’s drug from Eli Lilly for people with mild dementia. The FDA will make the final decision on approval later this year. If the agency agrees with its advisers, the drug ‘donanemab’ would only be the second Alzheimer’s drug cleared in the United States. to slow cognitive decline due to Alzheimer’s. Katherine Ward has this story and more in Health Matters for June 11, 2024.
Health Matters
Health Matters: U.S. FDA advisers endorse Alzheimer’s drug
More Videos
-
Health Matters: Canadian Food Inspection Agency triggers recall for Baby Gourmet cereal
-
Health Matters: 350k Bissell steam cleaners recalled in Canada over burn hazard
-
Health Matters: E-scooter injuries on the rise, Montreal Children’s Hospital warns
-
Health Matters: Psychotherapy, counselling now tax exempt
-
Health Matters: Unclear if Paris’ Seine River will be ready for Olympic swimmers
-
Health Matters: 5 bird flu cases identified on Colorado poultry farm
You are viewing an Accelerated Mobile Webpage.
View Original Article